CXCL13 antagonists and their use for the treatment of inflammatory diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 2, 2012
Grant Date -
Jan 17, 2008
app pub date -
Apr 20, 2007
filing date -
Apr 21, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully